Fatal Agranulocytosis and Fournier's Gangrene due to the Use of Metamizole.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Management of Fournier's gangrene during the Covid-19 pandemic era: make a virtue out of necessity.Basic and clinical andrology · 2022
   Article
2. Metamizole Use in Children: Analysis of Drug Utilisation and Adverse Drug Reactions at a German University Hospital between 2015 and 2020.Paediatric drugs · 2022
   Article
3. Fournier's Gangrene and Intravenous Drug Abuse: an Unusual Case Report and Review of The Literature.Open medicine (Warsaw, Poland) · 2019
   Article

Corrections and comments

• Commented on by
  Fatal Agranulocytosis and Fournier's Gangrene due to the Use of Metamizole: Correspondence.2019

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as